LIVZON PHARMAC. GRP H YC1 (LP6) — Cash Flow-to-Debt Ratio
LIVZON PHARMAC. GRP H YC1 (LP6) has a Cash Flow-to-Debt Ratio of 0.37x as of December 2025, meaning its operating cash flow of €3.15 Billion could theoretically repay 0% of its total liabilities (€8.44 Billion) in one year. Check LIVZON PHARMAC. GRP H YC1 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
LIVZON PHARMAC. GRP H YC1 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for LIVZON PHARMAC. GRP H YC1 across 5 annual periods. Also explore LIVZON PHARMAC. GRP H YC1 (LP6) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for LIVZON PHARMAC. GRP H YC1 (2021–2025)
Year-by-year debt coverage analysis for LIVZON PHARMAC. GRP H YC1. For market capitalisation and broader financial context, see LIVZON PHARMAC. GRP H YC1 (LP6) total market value.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | €3.15 Billion | €8.44 Billion | ▲ +19.5% |
| 2024 | 0.31x | €2.98 Billion | €9.55 Billion | ▼ -1.3% |
| 2023 | 0.32x | €3.25 Billion | €10.28 Billion | ▲ +13.2% |
| 2022 | 0.28x | €2.77 Billion | €9.93 Billion | ▲ +18.3% |
| 2021 | 0.24x | €1.90 Billion | €8.06 Billion | — |